Before The Commerce Committee

March 9, 2017

Testimony of CURE (Connecticut United for Research Excellence)

“Support For”

S.B. No. 962 (RAISED) - AN ACT CONCERNING THE DEVELOPMENT OF EVALUATIVE METRICS FOR BIOSCIENCE INVESTMENTS IN THE STATE

Co-Chair Hartley, Co-Chair Frantz, Co-Chair Simmons, Ranking Member Yaccarino, Vice Chair Reyes, Vice Chair Linares, Vice Chair Larson, Members of the Commerce Committee,

Ladies and Gentlemen:

My name is Dr. Susan Froshauer. I am the President and CEO of CURE, a 501(c)(3) organization that has for over 25 years represented the bioscience cluster of Connecticut. Our role at CURE is to educate and foster discussion on key topics affecting the growth and sustainability of Connecticut’s bioscience community. We have a strong membership comprised of individuals, investors, economic development organizations, universities, research institutes, small and large biopharmaceutical companies, medical device companies, and service providers.

CURE thanks the Commerce Committee for raising S.B. No. 962 and for this opportunity to testify. CURE supports this Bill because it can only help to strengthen and grow the vibrant biotechnology industry we have already established here in Connecticut. Consider the following:

- Nearly 25,000 people are employed by the bioscience industry in Connecticut
- The State has already invested heavily in the industry
- The State must protect and grow its investment
- The State must remain competitive in bioscience
- Bioscience is the future

Summary
For the foregoing reasons, CURE urges this Committee to progress S.B. No. 962. It is important to pursue the development of evaluative metrics for bioscience investments in the Connecticut, particularly if it is to remain competitive in biotechnology. The Bill is therefore in the best interest of the State’s biotechnology and pharmaceutical industries, and for developing new and innovative medicines and therapies for our people.

Thank you,

Susan Froshauer, PhD
President and CEO, CURE